CSF-1 Overexpression Predicts Poor Prognosis in Upper Tract Urothelial Carcinomas

Table 2

Univariate and multivariate analyses of disease-free survival and cancer-specific survival for upper tract urothelial carcinomas.

Variables	Item	Disease-free survival						Cancer-specific survival
		Univariate			Multivariate			Univariate			Multivariate
		HR	95% CI	value	HR	95% CI	value	HR	95% CI	value	HR	95% CI	value
Stage	III/IV	1.76	1.01-3.08	0.046	1.18	0.57-2.44	0.661	6.03	2.17-16.80	0.001	4.18	1.00-17.51	0.051
	I/II	1.00			1.00			1.00			1.00
Grade	High	1.15	0.61-2.17	0.659	1.05	0.50-2.22	0.902	1.65	0.55-4.99	0.376	0.63	0.14-2.86	0.547
	Low	1.00			1.00			1.00			1.00
Gender	Male	1.24	0.71-2.16	0.456	1.18	0.64-2.16	0.596	1.36	0.55-3.36	0.501	0.89	0.32-2.43	0.815
	Female	1.00			1.00			1.00			1.00
Age (years)	≥65	1.68	0.92-3.05	0.091	1.54	0.78-3.07	0.216	1.43	0.54-3.77	0.470	1.11	0.33-3.72	0.870
	<65	1.00			1.00			1.00			1.00
Tumor location	Renal pelvis + ureter	1.39	0.68-2.83	0.364	1.47	0.64-3.37	0.365	1.11	0.37-3.32	0.856	1.33	0.31-5.82	0.701
	Renal pelvis	0.76	0.40-1.45	0.406	0.67	0.34-1.31	0.243	0.56	0.19-1.68	0.301	0.42	0.13-1.34	0.143
	Ureter	1.00			1.00			1.00			1.00
Tumor side	Left	0.80	0.46-1.40	0.443	0.84	0.46-1.55	0.584	0.59	0.24-1.48	0.263	0.43	0.14-1.29	0.131
	Right	1.00			1.00			1.00			1.00
Lymphovascular invasion	Positive	1.35	0.72-2.55	0.351	1.13	0.54-2.39	0.745	2.49	0.97-6.34	0.057	2.15	0.69-6.70	0.186
	Negative	1.00			1.00			1.00			1.00
Creatinine (mg/dl)	>1.5	1.06	0.60-1.88	0.844	0.93	0.50-1.73	0.822	0.76	0.29-2.00	0.570	0.59	0.19-1.76	0.342
	≤1.5	1.00			1.00			1.00			1.00
CSF-1	High	2.14	1.20-3.81	0.010	2.56	1.30-5.04	0.007	5.18	1.71-15.71	0.004	5.14	1.27-20.84	0.022
	Low	1.00			1.00			1.00			1.00

Abbreviations: HR: hazard ratio; CI: confidence interval.